DAIICHI SANKYO CO LTD Share Price Today: Live Updates & Key Insights

DAIICHI SANKYO CO LTD share price today is $null, up null%. The stock opened at $null against the previous close of $null, with an intraday high of $null and low of $null.

DAIICHI SANKYO CO LTD Share Price Chart

DAIICHI SANKYO CO LTD

us-stock
To Invest in {{usstockname}}
us-stock

DAIICHI SANKYO CO LTD Share Price Performance

$null null(null%) null at 27 Jul 2026 02:45 PM Drug Manufacturers - General
Lowest Today 0.00
Highest Today 0.00
Today’s Open 0.00
Prev. Close 0.00
52 Week High 26.91
52 Week Low 14.98
Day’s Range: Low null High null
52-Week Range: Low 14.98 High 26.91
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

DAIICHI SANKYO CO LTD Institutional Holdings

DAIICHI SANKYO CO LTD Market Status

DAIICHI SANKYO CO LTD Fundamentals

Market Cap 30952.30 M

PB Ratio 3.0311

PE Ratio 19.7791

Enterprise Value 29234.42 M

Total Assets 4022762.05 M

Volume null

DAIICHI SANKYO CO LTD Company Financials

Annual Revenue FY26:2251081271000 2251081.3M, FY25:1886256000000 1886256.0M, FY24:1601688000000 1601688.0M, FY23:1278478000000 1278478.0M, FY22:1044892000000 1044892.0M

Annual Profit FY26:1541687608000 1541687.6M, FY25:1470458000000 1470458.0M, FY24:1186366000000 1186366.0M, FY23:914953000000 914953.0M, FY22:691564000000 691564.0M

Annual Net worth FY26:275546441000 275546.4M, FY25:295756000000 295756.0M, FY24:200731000000 200731.0M, FY23:109188000000 109188.0M, FY22:66972000000 66972.0M

Quarterly Revenue Q1/2026:600417340000 600417.3M, Q4/2025:568181298000 568181.3M, Q3/2025:509486000000 509486.0M, Q2/2025:474597000000 474597.0M, Q1/2025:518689000000 518689.0M

Quarterly Profit Q1/2026:292422205000 292422.2M, Q4/2025:447767048000 447767.0M, Q3/2025:350786000000 350786.0M, Q2/2025:382251000000 382251.0M, Q1/2025:424351000000 424351.0M

Quarterly Net worth Q1/2026:43207449000 43207.4M, Q4/2025:88195938000 88195.9M, Q3/2025:46104000000 46104.0M, Q2/2025:85500000000 85500.0M, Q1/2025:87153000000 87153.0M

About DAIICHI SANKYO CO LTD & investment objective

Company Information Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Organisation Drug Manufacturers - General

Employees 20171

Industry Drug Manufacturers - General

CEO Mr. Hiroyuki Okuzawa

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

DAIICHI SANKYO CO LTD FAQs

What is the share price of DAIICHI SANKYO CO LTD today?

The current share price of DAIICHI SANKYO CO LTD is $null.

Can I buy DAIICHI SANKYO CO LTD shares in India?

Yes, Indian investors can buy DAIICHI SANKYO CO LTD shares by opening an international trading and demat account with Motilal Oswal.

How to buy DAIICHI SANKYO CO LTD shares in India?

You can easily invest in DAIICHI SANKYO CO LTD shares from India by:

Can I buy fractional shares of DAIICHI SANKYO CO LTD?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of DAIICHI SANKYO CO LTD?

DAIICHI SANKYO CO LTD has a market cap of $30952.30 M.

In which sector does DAIICHI SANKYO CO LTD belong?

DAIICHI SANKYO CO LTD operates in the Drug Manufacturers - General sector.

What documents are required to invest in DAIICHI SANKYO CO LTD stocks?

To invest, you typically need:

What is the PE and PB ratio of DAIICHI SANKYO CO LTD?

The PE ratio of DAIICHI SANKYO CO LTD is 19.78 and the PB ratio is 3.03.